CAR Immunotherapy for the treatment of infectious diseases: a systematic review
Frontiers in Immunology, ISSN: 1664-3224, Vol: 15, Page: 1289303
2024
- 6Citations
- 38Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations6
- Citation Indexes6
- Captures38
- Readers38
- 38
- Mentions1
- News Mentions1
- News1
Most Recent News
Hospital Clinico Universitario Lozano Blesa Researchers Add New Study Findings to Research in Infectious Diseases and Conditions (CAR Immunotherapy for the treatment of infectious diseases: a systematic review)
2024 FEB 09 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Daily -- Current study results on infectious diseases and conditions have been
Review Description
Immunotherapy treatments aim to modulate the host’s immune response to either mitigate it in inflammatory/autoimmune disease or enhance it against infection or cancer. Among different immunotherapies reaching clinical application during the last years, chimeric antigen receptor (CAR) immunotherapy has emerged as an effective treatment for cancer where different CAR T cells have already been approved. Yet their use against infectious diseases is an area still relatively poorly explored, albeit with tremendous potential for research and clinical application. Infectious diseases represent a global health challenge, with the escalating threat of antimicrobial resistance underscoring the need for alternative therapeutic approaches. This review aims to systematically evaluate the current applications of CAR immunotherapy in infectious diseases and discuss its potential for future applications. Notably, CAR cell therapies, initially developed for cancer treatment, are gaining recognition as potential remedies for infectious diseases. The review sheds light on significant progress in CAR T cell therapy directed at viral and opportunistic fungal infections.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85185294205&origin=inward; http://dx.doi.org/10.3389/fimmu.2024.1289303; http://www.ncbi.nlm.nih.gov/pubmed/38352878; https://www.frontiersin.org/articles/10.3389/fimmu.2024.1289303/full; https://dx.doi.org/10.3389/fimmu.2024.1289303; https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1289303/full
Frontiers Media SA
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know